Amarantus Bioscience Holdings Inc (AMBS)

[1~Eye~Jack!!]

~ AMBS = Zach's Report: Despite what we believe is aggressive discounting and
downward adjusting of our models based on overly
pessimistic probability assumptions, we are still arriving at a
target price of $1.00 per share. The current market
capitalization is only $2 million. Our target is far more
consistent with that we see as a peer-valuation for similar- stage NASDAQ listed companies. We believe several pending
catalysts over the next 15 months, including the AMDX sales /
spin-off, starting human clinical trials with MANF, reporting
results from the eltoprazine Phase IIb data, and the ESS
Phase IIa data should allow for the realization of a significantly
higher stock price.